76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Accuray Inc
Open
SectorHealthcare
1.24 -0.8
Overview
Share price change
24h
Min
1.19
Max
1.26
Income | -3.8M -1.3M |
|---|---|
Sales | -2.9M 113M |
EPS | -0.01 |
Profit margin | -1.145 |
Employees | 987 |
EBITDA | -6.6M 1M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +337.4% upside |
Next Earnings | 13 Aug 2025 |
|---|
Market Cap | -39M 127M |
|---|---|
Previous open | 2.04 |
Previous close | 1.24 |
News Sentiment
By Acuity
23%
77%
36 / 381 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Accuray Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Accuray Inc Forecast
Price Target
By TipRanks
337.4% upside
12 Months Forecast
Average 5.38 USD 337.4%
High 7 USD
Low 4 USD
Based on 4 Wall Street analysts offering 12 month price targets forAccuray Inc - Dist in the last 3 months.
Sentiment
By Acuity
36 / 381 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Accuray Inc
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
